23andMe Holding Co. (ME) EV/Sales Ratio: 0.02x
Is 23andMe Holding Co.’s EV/Sales ratio high or low?
23andMe Holding Co.'s EV/Sales ratio of 0.02x is 99% below its 5-year average of 3.53x, near the low end of its 5-year range (0.00x–21.42x).
As of Monday, June 15, 2026. 94.36% below its 12-month average of 0.35x.
ME EV/Sales Ratio Chart
ME Average EV/Sales Ratio Chart
ME Current vs Average EV/Sales Ratio Chart
ME EV/Sales Ratio Metrics
EV/SALES RATIO
0.02x
EV/SALES RATIO AVG TTM
0.35x
EV/SALES RATIO AVG 3Y
0.64x
EV/SALES RATIO AVG 5Y
1.86x
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-94.36%
CURRENT VS 3Y AVG
-96.86%
CURRENT VS 5Y AVG
-98.93%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ME Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 23andMe Holding Co. (ME) | $15.31M | 0.02x | 0.35x | 0.64x | 1.86x |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.02B | 1.13x | 1.27x | 1.71x | 2.18x |
| Hims & Hers Health, Inc. (HIMS)vs › | $5.98B | 2.97x | 4.71x | 4.20x | 4.27x |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.73B | 3.31x | 3.41x | 3.67x | 4.57x |
| Tempus AI, Inc. (TEM)vs › | $8.35B | 6.86x | 11.47x | 12.19x | 12.19x |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.03B | 2.99x | 2.79x | 3.02x | 3.79x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 0.25x | 0.26x | 0.37x | 0.45x |
| Baxter International Inc. (BAX)vs › | $10.77B | 1.63x | 1.72x | 2.17x | 2.64x |
| Align Technology, Inc. (ALGN)vs › | $12.52B | 2.83x | 2.73x | 4.07x | 5.90x |
| The Cooper Companies, Inc. (COO)vs › | $13.24B | 3.68x | 4.15x | 5.16x | 5.81x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
23andMe Holding Co. EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
23andMe Holding Co. EV/Sales Ratio FAQ
- What is the EV/Sales ratio for 23andMe Holding Co. (ME)?
- The EV/Sales ratio for ME stock is 0.02x.
- Is 23andMe Holding Co.'s EV/Sales ratio high or low?
- 23andMe Holding Co.'s EV/Sales ratio of 0.02x is 99% below its 5-year average of 3.53x, near the low end of its 5-year range (0.00x–21.42x).
- What is the TTM average EV/Sales ratio for 23andMe Holding Co. (ME)?
- The TTM average EV/Sales ratio for ME stock is 0.35x.
- What is the 3Y average EV/Sales ratio for 23andMe Holding Co. (ME)?
- The 3Y average EV/Sales ratio for ME stock is 0.64x.
- What is the 5Y average EV/Sales ratio for 23andMe Holding Co. (ME)?
- The 5Y average EV/Sales ratio for ME stock is 1.86x.
23andMe Holding Co. EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-03-19 | 0.02x |
| 2026-03-09 | 0.02x |
| 2026-03-02 | 0.02x |
| 2026-02-10 | 0.02x |
| 2026-01-30 | 0.02x |
| 2025-11-25 | 0.02x |
| 2025-07-14 | 0.83x |
| 2025-07-11 | 0.83x |
| 2025-07-10 | 0.83x |
| 2025-07-09 | 0.80x |
| 2025-07-08 | 0.79x |
| 2025-07-07 | 0.81x |
| 2025-07-03 | 0.83x |
| 2025-07-02 | 0.83x |
| 2025-07-01 | 0.83x |
| 2025-06-30 | 0.83x |
| 2025-06-27 | 0.75x |
| 2025-06-26 | 0.74x |
| 2025-06-25 | 0.74x |
| 2025-06-24 | 0.74x |
| 2025-06-23 | 0.75x |
| 2025-06-20 | 0.75x |
| 2025-06-18 | 0.77x |
| 2025-06-17 | 0.70x |
| 2025-06-16 | 0.73x |
| 2025-06-13 | 0.91x |
| 2025-06-12 | 0.86x |
| 2025-04-28 | 0.11x |
| 2025-04-25 | 0.09x |
| 2025-04-24 | 0.09x |
| 2025-04-23 | 0.07x |
| 2025-04-22 | 0.07x |
| 2025-04-21 | 0.07x |
| 2025-04-17 | 0.07x |
| 2025-04-16 | 0.07x |
| 2025-04-15 | 0.07x |
| 2025-04-14 | 0.07x |
| 2025-04-11 | 0.06x |
| 2025-04-10 | 0.06x |
| 2025-04-09 | 0.04x |
| 2025-04-08 | 0.06x |
| 2025-04-07 | 0.06x |
| 2025-04-04 | 0.08x |
| 2025-04-03 | 0.04x |
| 2025-04-02 | 0.07x |
| 2025-04-01 | 0.01x |
| 2025-03-31 | 0.00x |
| 2025-03-27 | 0.01x |
| 2025-03-24 | 0.00x |
| 2025-03-21 | 0.14x |
| 2025-03-20 | 0.13x |
| 2025-03-19 | 0.14x |
| 2025-03-18 | 0.15x |
| 2025-03-17 | 0.16x |
| 2025-03-14 | 0.15x |
| 2025-03-13 | 0.14x |
| 2025-03-12 | 0.13x |
| 2025-03-11 | 0.11x |
| 2025-03-10 | 0.10x |
| 2025-03-07 | 0.10x |
| 2025-03-06 | 0.10x |
| 2025-03-05 | 0.10x |
| 2025-03-04 | 0.08x |
| 2025-03-03 | 0.10x |
| 2025-02-28 | 0.19x |
| 2025-02-27 | 0.19x |
| 2025-02-26 | 0.19x |
| 2025-02-25 | 0.19x |
| 2025-02-24 | 0.20x |
| 2025-02-21 | 0.22x |
| 2025-02-20 | 0.26x |
| 2025-02-19 | 0.25x |
| 2025-02-18 | 0.26x |
| 2025-02-14 | 0.23x |
| 2025-02-13 | 0.22x |
| 2025-02-12 | 0.22x |
| 2025-02-11 | 0.23x |
| 2025-02-10 | 0.23x |
| 2025-02-07 | 0.23x |
| 2025-02-06 | 0.24x |
| 2025-02-05 | 0.06x |
| 2025-02-04 | 0.08x |
| 2025-02-03 | 0.09x |
| 2025-01-31 | 0.13x |
| 2025-01-30 | 0.17x |
| 2025-01-29 | 0.17x |
| 2025-01-28 | 0.16x |
| 2025-01-27 | 0.16x |
| 2025-01-24 | 0.18x |
| 2025-01-23 | 0.18x |
| 2025-01-22 | 0.18x |
| 2025-01-21 | 0.19x |
| 2025-01-17 | 0.19x |
| 2025-01-16 | 0.19x |
| 2025-01-15 | 0.17x |
| 2025-01-14 | 0.16x |
| 2025-01-13 | 0.20x |
| 2025-01-10 | 0.22x |
| 2025-01-08 | 0.25x |
| 2025-01-07 | 0.24x |
| 2025-01-06 | 0.22x |
| 2025-01-03 | 0.22x |
| 2025-01-02 | 0.18x |
| 2024-12-31 | 0.15x |
| 2024-12-30 | 0.15x |
| 2024-12-27 | 0.15x |
| 2024-12-26 | 0.15x |
| 2024-12-24 | 0.13x |
| 2024-12-23 | 0.14x |
| 2024-12-20 | 0.15x |
| 2024-12-19 | 0.12x |
| 2024-12-18 | 0.13x |
| 2024-12-17 | 0.14x |
| 2024-12-16 | 0.16x |
| 2024-12-13 | 0.16x |
| 2024-12-12 | 0.16x |
| 2024-12-11 | 0.20x |
| 2024-12-10 | 0.22x |
| 2024-12-09 | 0.24x |
| 2024-12-06 | 0.25x |
| 2024-12-05 | 0.19x |
| 2024-12-04 | 0.17x |
| 2024-12-03 | 0.18x |
| 2024-12-02 | 0.19x |
| 2024-11-29 | 0.18x |
| 2024-11-27 | 0.13x |
| 2024-11-26 | 0.13x |
| 2024-11-25 | 0.15x |
| 2024-11-22 | 0.13x |
| 2024-11-21 | 0.14x |
| 2024-11-20 | 0.13x |
| 2024-11-19 | 0.17x |
| 2024-11-18 | 0.09x |
| 2024-11-15 | 0.11x |
| 2024-11-14 | 0.22x |
| 2024-11-13 | 0.28x |
| 2024-11-12 | 0.34x |
| 2024-10-03 | 0.15x |
| 2024-10-02 | 0.15x |
| 2024-10-01 | 0.10x |
| 2024-09-30 | 0.05x |
| 2024-09-24 | 0.03x |
| 2024-09-23 | 0.03x |
| 2024-09-20 | 0.03x |
| 2024-09-19 | 0.01x |
| 2024-09-18 | 0.02x |
| 2024-09-17 | 0.03x |
| 2024-09-16 | 0.04x |
| 2024-09-13 | 0.03x |
| 2024-08-26 | 0.02x |
| 2024-08-21 | 0.01x |
| 2024-08-20 | 0.07x |
| 2024-08-19 | 0.08x |
| 2024-08-16 | 0.04x |
| 2024-08-15 | 0.01x |
| 2024-08-14 | 0.02x |
| 2024-08-13 | 0.05x |
| 2024-08-12 | 0.09x |
| 2024-08-09 | 0.08x |
| 2024-08-08 | 0.11x |
| 2024-08-07 | 0.18x |
| 2024-08-06 | 0.17x |
| 2024-08-05 | 0.16x |
| 2024-08-02 | 0.20x |
| 2024-08-01 | 0.20x |
| 2024-07-31 | 0.24x |
| 2024-07-30 | 0.26x |
| 2024-07-29 | 0.33x |
| 2024-07-26 | 0.33x |
| 2024-07-25 | 0.35x |
| 2024-07-24 | 0.35x |
| 2024-07-23 | 0.38x |
| 2024-07-22 | 0.37x |
| 2024-07-19 | 0.33x |
| 2024-07-18 | 0.41x |
| 2024-07-17 | 0.49x |
| 2024-07-16 | 0.48x |
| 2024-07-15 | 0.43x |
| 2024-07-12 | 0.42x |
| 2024-07-11 | 0.40x |
| 2024-07-10 | 0.37x |
| 2024-07-09 | 0.35x |
| 2024-07-08 | 0.30x |
| 2024-07-05 | 0.30x |
| 2024-07-03 | 0.30x |
| 2024-07-02 | 0.22x |
| 2024-07-01 | 0.19x |
| 2024-06-28 | 0.22x |
| 2024-06-27 | 0.29x |
| 2024-06-26 | 0.25x |
| 2024-06-25 | 0.33x |
| 2024-06-24 | 0.33x |
| 2024-06-21 | 0.29x |
| 2024-06-20 | 0.28x |
| 2024-06-18 | 0.26x |
| 2024-06-17 | 0.24x |
| 2024-06-14 | 0.23x |
| 2024-06-13 | 0.27x |
| 2024-06-12 | 0.27x |
| 2024-06-11 | 0.27x |
| 2024-06-10 | 0.25x |
| 2024-06-07 | 0.25x |
| 2024-06-06 | 0.28x |
| 2024-06-05 | 0.33x |
| 2024-06-04 | 0.35x |
| 2024-06-03 | 0.53x |
| 2024-05-31 | 0.56x |
| 2024-05-30 | 0.59x |
| 2024-05-29 | 0.52x |
| 2024-05-28 | 0.40x |
| 2024-05-24 | 0.33x |
| 2024-05-23 | 0.33x |
| 2024-05-22 | 0.36x |
| 2024-05-21 | 0.37x |
| 2024-05-20 | 0.40x |
| 2024-05-17 | 0.48x |
| 2024-05-16 | 0.50x |
| 2024-05-15 | 0.47x |
| 2024-05-14 | 0.52x |
| 2024-05-13 | 0.37x |
| 2024-05-10 | 0.30x |
| 2024-05-09 | 0.33x |
| 2024-05-08 | 0.28x |
| 2024-05-07 | 0.30x |
| 2024-05-06 | 0.28x |
| 2024-05-03 | 0.31x |
| 2024-05-02 | 0.32x |
| 2024-05-01 | 0.31x |
| 2024-04-30 | 0.31x |
| 2024-04-29 | 0.34x |
| 2024-04-26 | 0.24x |
| 2024-04-25 | 0.23x |
| 2024-04-24 | 0.25x |
| 2024-04-23 | 0.30x |
| 2024-04-22 | 0.23x |
| 2024-04-19 | 0.28x |
| 2024-04-18 | 0.32x |
| 2024-04-17 | 0.03x |
| 2024-04-16 | 0.10x |
| 2024-04-15 | 0.12x |
| 2024-04-12 | 0.20x |
| 2024-04-11 | 0.24x |
| 2024-04-10 | 0.25x |
| 2024-04-09 | 0.28x |
| 2024-04-08 | 0.26x |
| 2024-04-05 | 0.27x |
| 2024-04-04 | 0.25x |
| 2024-04-03 | 0.34x |
| 2024-04-02 | 0.37x |
| 2024-04-01 | 0.36x |
| 2024-03-28 | 0.37x |
| 2024-03-27 | 0.33x |
| 2024-03-26 | 0.29x |
| 2024-03-25 | 0.21x |
| 2024-03-22 | 0.12x |
| 2024-03-21 | 0.19x |
| 2024-03-20 | 0.26x |
| 2024-03-19 | 0.25x |
| 2024-03-18 | 0.25x |
| 2024-03-15 | 0.20x |
Showing the most recent 260 of 960 data points. The chart above shows the full history.
Related Metrics
About 23andMe Holding Co.
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joseph Selsavage